<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451448</url>
  </required_header>
  <id_info>
    <org_study_id>17/SS/0151</org_study_id>
    <nct_id>NCT03451448</nct_id>
  </id_info>
  <brief_title>PET MRI in Coronary Artery Disease</brief_title>
  <official_title>Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the use of position emission tomography/magnetic resonance imaging&#xD;
      (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast&#xD;
      agent in patients with coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron emission tomography/magnetic resonance imaging (PET/MRI) has the potential to&#xD;
      provide detailed information on coronary artery anatomy, the presence of coronary artery&#xD;
      stenosis, the composition of atherosclerotic plaque using MRI tissue characterisation and&#xD;
      information about the underlying biological processes using targeted PET tracers.&#xD;
      Ultra-small-superparamagnetic particles of iron oxide (USPIO) have a long blood pool&#xD;
      half-life so are an ideal contrast agent for PET/MRI imaging.&#xD;
&#xD;
      This study will assess the use of PET/MRI with USPIO in patients with stable coronary artery&#xD;
      disease and recent acute myocardial infarction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PET/MRI findings</measure>
    <time_frame>Immediately after PET/MRI scan</time_frame>
    <description>The primary endpoint will be the difference in MRI and PET characteristics of atherosclerotic plaques in patients with and without recent acute coronary syndromes.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Healthy volunteers to undergo MRI using USPIO contrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable coronary artery disease</arm_group_label>
    <description>Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recent acute coronary syndrome</arm_group_label>
    <description>Patients with recent (3 months) type 1 myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>PET/MRI with USPIO contrast</description>
    <arm_group_label>Recent acute coronary syndrome</arm_group_label>
    <arm_group_label>Stable coronary artery disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI with USPIO contrast</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers to undergo MRI.&#xD;
&#xD;
        Patients with stable coronary artery disease or recent acute myocardial infarction to&#xD;
        undergo PET/MRI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to&#xD;
             provide informed consent.&#xD;
&#xD;
          -  Patients with coronary artery disease to undergo PET/MRI will have multi-vessel&#xD;
             disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal&#xD;
             stenosis).&#xD;
&#xD;
          -  able to provide informed consent&#xD;
&#xD;
          -  over the age of 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability or unwillingness to undergo magnetic resonance imaging or positron emission&#xD;
             tomography&#xD;
&#xD;
          -  renal failure (Serum creatinine &gt;200 umol/L or estimated glomerular filtration rate&#xD;
             &lt;30 mL/min&#xD;
&#xD;
          -  hepatic failure&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
          -  contraindications to undergoing MRI scanning&#xD;
&#xD;
          -  contraindications to contrast agents not included above including evidence of iron&#xD;
             overload, known allergy to constituents of the contrast agents, and anaemia not caused&#xD;
             by iron deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>ultra-small-superparamagnetic particles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

